Optimize Your Drug Development Decisions With Certara
Certara® is the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. The company provides regulatory strategy, model-informed drug development services and technology, and regulatory writing and submission services. We offer a wide range of products, services and solutions that enable our clients to achieve key drug development, regulatory and commercial milestones. Our portfolio spans the discovery, preclinical, clinical and post-marketing phases of drug development, working with 1,200 commercial companies, 250 academic institutions and numerous regulatory agencies around the world.
Decades of Experience Optimizing Drug Development
Certara was formed in 2008 by the merger of Tripos®International, the leading provider of drug discovery informatics products and services, with the Pharsight® Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development. In 2012, the ability to provide innovation solutions to the pharmaceutical industry was further augmented with the acquisition of Simcyp® Limited, the leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations. The following year, the acquisition of Great Lakes Drug Development, Inc further increased the depth of Certara’s early drug development analysis, and modeling and simulation capabilities.
Seeking to add global regulatory writing and submission services to Certara’s drug development consulting expertise, the addition of Synchrogenix® occurred in 2014. In early 2015, Certara’s regulatory and medical writing consultancy, Synchrogenix, acquired ClinGenuityTM, the only artificial intelligence-assisted medical writing service in the pharmaceutical industry. Later that year, Certara created the preeminent global strategic modeling and simulation consultancy through the merger of its consulting group, Pharsight Consulting Services, with Quantitative SolutionsTM, an international pharmacometrics consulting company. At the end of 2015, Certara created a division within Simcyp focused on Quantitative Systems Pharmacology through the acquisition of XenologiQ, led by Dr. Piet van der Graaf. In September, 2016, the company expanded its consulting footprint through the acquisition of d3 Medicine, a global organization focused on strategic planning and stewardship of complex drug development programs.
Through the years, Certara has evolved and continues to grow to provide our clients with solutions, spanning the discovery, preclinical and clinical stages of drug development, that enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety.
Optimizing Drug Development Decisions
Drug Development and Regulatory Strategy | Modeling and Simulation | Regulatory and Medical Writing
Certara is proud to have received several prestigious awards over recent years. These include:
‘NJBIZ Business of the Year Finalist’
Certara was named a finalist in the “Business of the Year (100+ employees)” category of the NJBIZ Business of the Year program.
‘R&D 100 Awards Finalist’
Certara’s Muse® InventTM was named a finalist in the “Software/Services” category of the R&D 100 Awards program.
‘NJBIZ Healthcare Heroes Finalist’
Certara was named a finalist in the “Innovation Hero” category of the NJBIZ Healthcare Heroes program.
‘Cool Vendor Designation by Gartner’
Certara’s ClinGenuity was named a “Cool Vendor” in Gartner, Inc.’s 2015 Life Sciences report.
‘Society of Toxicology Outstanding Paper Award’
Authored by The Hamner Institutes for Health Sciences, the EPA, and Certara, this award-winning paper uses high-throughput toxicity testing to compare susceptibility between populations.
‘American Association of Pharmaceutical Scientists Fellowship’
Amin Rostami, Pharm.D., Ph.D., FCP, was selected as a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in recognition of his professional excellence and contributions to the fields of pharmacokinetics and pharmacology.
‘The Queen’s Award for Enterprise’
This award has been made in the Innovation category and reflects Simcyp’s continuous development of modeling and simulation software for evaluating drugs in the safety of a computer.